Weekly docetaxel combined with cisplatin versus weekly docetaxel combined with oxaliplatin in the treatment of advanced gastric cancer

王涛; 赵磊; 李榆

doi:10.3969/j.issn.1007-3969.2015.02.012

您当前的位置：

首页 >

文章列表页 >

Weekly docetaxel combined with cisplatin versus weekly docetaxel combined with oxaliplatin in the treatment of advanced gastric cancer

更新时间：2025-12-31

- Weekly docetaxel combined with cisplatin versus weekly docetaxel combined with oxaliplatin in the treatment of advanced gastric cancer
- China Oncology Vol. 25, Issue 2, Pages: 150-154(2015)
- 作者机构：
  
  兰州大学第二医院 VIP 外科,甘肃,兰州,730000
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.02.012
  CLC：
- Published Online：13 May 2015，
  
  Published：13 May 2015
- 稿件说明：
移动端阅览
王涛,赵磊,李榆,等. 周剂量多西他赛联合顺铂与周剂量多西他赛联合奥沙利铂治疗晚期胃癌的临床研究[J]. 中国癌症杂志, 2015, 25(2): 150-154.

王涛, 赵磊, 李榆. Weekly docetaxel combined with cisplatin versus weekly docetaxel combined with oxaliplatin in the treatment of advanced gastric cancer[J]. China Oncology, 2015, 25(2): 150-154.
王涛,赵磊,李榆,等. 周剂量多西他赛联合顺铂与周剂量多西他赛联合奥沙利铂治疗晚期胃癌的临床研究[J]. 中国癌症杂志, 2015, 25(2): 150-154. DOI： 10.3969/j.issn.1007-3969.2015.02.012.

王涛, 赵磊, 李榆. Weekly docetaxel combined with cisplatin versus weekly docetaxel combined with oxaliplatin in the treatment of advanced gastric cancer[J]. China Oncology, 2015, 25(2): 150-154. DOI： 10.3969/j.issn.1007-3969.2015.02.012.

摘要

背景与目的：已有研究证实，多西他赛联合顺铂(docetaxel plus cisplatin，DP)或多西他赛联合奥沙利铂(docetaxel plus oxaliplatin，DO)治疗晚期胃癌具有较好的疗效。本研究旨在观察周剂量多西他赛联合顺铂与周剂量多西他赛联合奥沙利铂一线治疗晚期胃癌的疗效及不良反应。方法：76例胃癌患者随机分为两组，每组38例，DP组多西他赛35 mg/m

，静脉滴注，第1、8天，顺铂60 mg/m

，静脉滴注，第1天，21 d为1个周期；DO组多西他赛35 mg/m

，静脉滴注，第1、8天，奥沙利铂120 mg/m

，静脉滴注，第1天，21 d为1个周期。结果：DP组总有效率为37%，中位无进展生存期为4.9个月，中位生存期为9.7个月；DO组总有效率为41%，中位无进展生存期为4.4个月，中位生存期为12.3个月。两组的总有效率(P=0.707)、中位无进展生存期(P=0.324)、中位生存期(P=0.581)差异均无统计学意义。两组的3/4级不良反应都是中性粒细胞减少，DP组恶心、呕吐发生率较高(P0.05)，而DO组周围神经病变发生率较高(P0.05)；两组贫血、血小板减少、脱发、腹泻和肝功能损害等不良反应差异均无统计学意义(P0.05)。结论：DP和DO一线治疗晚期胃癌的疗效及不良反应相仿，值得临床进一步研究。

Abstract

Background and purpose: It has confirmed that docetaxel

in combination with cisplatin or oxaliplatin have good effect in the treatment of advanced gastric cancer. This study in order to observe the clinical efficacy and adverse reaction of weekly docetaxel combined with cisplatin (DP) versus weekly docetaxel combined with oxaliplatin (DO) as the firrst-line treatment of advanced gastric cancer. Methods: A total number of 76 cases of advanced gastric cancer were randomly assigned 2 arms

38 per arm. DP regimen group (docetaxel 35 mg/

ivgtt

d8 combined with cisplatin 60 mg/m

ivgtt

repeated every 3 weeks) and DO regimen group(docetaxel 35 mg/m

ivgtt

d8 combined with oxaliplatin 120 mg/m

ivgtt

repeated every 3 weeks). Results: No significant difference was found between DP regimen group and DO regimen group on the objective RR(37% vs 41%)，PFS (4.9 vs 4.4 months) and OS (9.7 vs 12.3 months). The main grade 3 or 4 toxicity in the DP and DO groups was neutropenia

DO was less associated with nausea and vomiting

but more associated with peripheral neuropathy than DP group. No significant difference was found between DP regimen group and DO regimen group on the anemia

thrombocytopenia

diarrhea

alopecia (P0.05).Conclusion: Weekly docetaxel combined with cisplatin (DP) shows similar efficacy and toxicity compared with weekly docetaxel combined with oxaliplatin (DO) as the first-line treatment of advanced gastric cancer and worthy of further study.

关键词

Keywords

references

Views

2381

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exosomal transfer of macrophage-derived miR-223 confers oxaliplatin resistance in gastric cancer

The selection and application of platinum drugs in the treatment of head and neck squamous cell carcinomas

The clinical effects of pemetrexed or docetaxel combined with cisplatin as the first line treatment for advanced lung adenocarcinoma

The clinical evaluation of EOF5 regimen, the combination of epirubicin, oxaliplatin and 5-day continuous infusion of 5-FU, for patients with advanced/metastatic gastric cancer

S-1 plus oxaliplatin for the treatment of advanced small bowel adenocarcinoma

Related Author

郑培明

李俊蒙

张　鹏

高　岚

李文成

王孝深

周　娟

贲素琴

Related Institution

河南省人民医院检验科

河南省人民医院胃肠外科

安徽医科大学第一附属医院放疗科

复旦大学附属肿瘤医院放疗科，复旦大学上海医学院肿瘤学系

南通大学附属医院呼吸科

AI问答

⁰